Physician profile

Samyuktha Devabhaktuni

Family Medicine · Mesa, AZ

NPI 1407273865

$1,979.59

in general payments reported to CMS, 2019-2025

25 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $343.24 2019-2021
Novo Nordisk INC $240.57 2019-2021
Janssen Pharmaceuticals, INC $178.63 2019-2021
Boehringer Ingelheim Pharmaceuticals, INC. $148.72 2019-2021
Amgen INC. $147.27 2019-2021
Glaxosmithkline, LLC. $145.39 2019-2021
Eisai INC. $136.63 2020-2021
Abbott Laboratories $88.99 2019-2022
Merck Sharp & Dohme LLC $67.79 2019-2021
Astellas Pharma US INC $61.00 2021
Radius Health, INC. $54.70 2019
Takeda Pharmaceuticals U.S.A., INC. $48.15 2019-2021
Novartis Pharmaceuticals Corporation $43.35 2019-2021
Lilly USA, LLC $42.19 2019
Nestle Healthcare Nutrition INC. $40.71 2021
Show all 25 companies
CompanyGeneral paymentsYearsTop products
Sanofi-Aventis U.S. LLC $31.30 2019
Topcon Healthcare Solutions, INC. $27.93 2019
Ge Healthcare $21.96 2019
Arbor Pharmaceuticals, INC. $19.71 2020
Dermira, INC. $19.42 2020
Vanda Pharmaceuticals INC. $18.39 2021
Almatica Pharma LLC $14.74 2021
Medtronic Vascular, INC. $13.95 2020
Pfizer INC. $12.47 2019
Sanofi Pasteur INC. $12.39 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Samyuktha Devabhaktuni

$1,979.59

in general payments reported 2019-2025

Years
2019-2022
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/3739733/samyuktha-devabhaktuni

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.